421 related articles for article (PubMed ID: 8632309)
1. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
[TBL] [Abstract][Full Text] [Related]
3. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
4. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
Schuh KJ; Walsh SL; Bigelow GE; Preston KL; Stitzer ML
J Pharmacol Exp Ther; 1996 Aug; 278(2):836-46. PubMed ID: 8768738
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
[TBL] [Abstract][Full Text] [Related]
7. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
[TBL] [Abstract][Full Text] [Related]
8. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
[TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
13. Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions.
Eissenberg T; Stitzer ML; Bigelow GE; Buchhalter AR; Walsh SL
J Pharmacol Exp Ther; 1999 May; 289(2):936-45. PubMed ID: 10215673
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Stinus L; Cador M; Zorrilla EP; Koob GF
Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine and naloxone interactions in methadone maintenance patients.
Mendelson J; Jones RT; Welm S; Brown J; Batki SL
Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
[TBL] [Abstract][Full Text] [Related]
16. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
[TBL] [Abstract][Full Text] [Related]
17. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
Rosado J; Walsh SL; Bigelow GE; Strain EC
Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
[TBL] [Abstract][Full Text] [Related]
18. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine: considerations for pain management.
Johnson RE; Fudala PJ; Payne R
J Pain Symptom Manage; 2005 Mar; 29(3):297-326. PubMed ID: 15781180
[TBL] [Abstract][Full Text] [Related]
20. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
Holtzman SG
J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
